EVA treatment for recurrent or unresponsive Hodgkin's disease

Area of Science:

• Oncology
• Hematology
• Clinical Pharmacology

Background:

• Hodgkin's disease is a cancer of the lymphatic system.
• Recurrent or unresponsive Hodgkin's disease often requires salvage chemotherapy.
• Previous standard treatments include mustine, vinblastine, prednisolone, and procarbazine (MVPP or ChlVPP).

Purpose of the Study:

• To evaluate the efficacy and safety of the etoposide, vincristine, and adriamycin (EVA) combination chemotherapy.
• To assess EVA's effectiveness in patients with recurrent or unresponsive Hodgkin's disease previously treated with MVPP or ChlVPP.
• To determine if EVA exhibits cross-resistance with prior chemotherapy regimens.

Main Methods:

• Nineteen patients with recurrent or unresponsive Hodgkin's disease were enrolled.
• Patients had previously received MVPP or ChlVPP chemotherapy.
• Treatment consisted of etoposide, vincristine, and adriamycin (EVA) combination therapy.

Main Results:

• Eleven out of nineteen patients (58%) achieved clinical remission (complete or good partial).
• Remission rates were comparable between patients who previously responded well and those who responded poorly to chemotherapy.
• Myelosuppression was the primary toxicity, generally manageable.

Conclusions:

• The EVA regimen demonstrated potential non-cross-resistance with MVPP and ChlVPP.
• EVA shows promise as a salvage chemotherapy option for Hodgkin's disease.
• While not curative for treatment failures, EVA may be valuable for previously untreated patients.